Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: paracrine gene therapy - Renova

Drug Profile

Research programme: paracrine gene therapy - Renova

Alternative Names: AAV8.UCn2; Adeno-associated virus 8 vector encoding urocortin 2 - Renova Therapeutics; RT-110; RT-200; RT-210; RT-220; RT-230; RT-300; Urocortin-2 gene therapy - Renova

Latest Information Update: 28 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of California, San Diego
  • Developer Renova Therapeutics
  • Class Antihyperglycaemics; Cardiovascular therapies; Gene therapies; Hepatoprotectants; Obesity therapies
  • Mechanism of Action Adenylate cyclase stimulants; Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • No development reported Heart failure; Non-alcoholic fatty liver disease; Obesity; Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 28 Jul 2022 No recent reports of development identified for preclinical development in Type-1 diabetes mellitus in USA (IV, Injection)
  • 28 Mar 2020 No recent reports of development identified for preclinical development in Heart-failure in USA (IV)
  • 28 Jun 2019 No recent reports of development identified for preclinical development in Heart-failure in USA (Intracoronary)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top